151 related articles for article (PubMed ID: 10858434)
1. Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation.
Berrada K; Plesnicher CL; Luo X; Thibonnier M
J Biol Chem; 2000 Sep; 275(35):27229-37. PubMed ID: 10858434
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the G protein-coupled receptor kinase GRK5 by protein kinase C.
Pronin AN; Benovic JL
J Biol Chem; 1997 Feb; 272(6):3806-12. PubMed ID: 9013639
[TBL] [Abstract][Full Text] [Related]
3. Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus.
Hawtin SR; Wesley VJ; Parslow RA; Patel S; Wheatley M
Biochemistry; 2000 Nov; 39(44):13524-33. PubMed ID: 11063589
[TBL] [Abstract][Full Text] [Related]
4. Role of cytoplasmic tail of the type 1A angiotensin II receptor in agonist- and phorbol ester-induced desensitization.
Tang H; Guo DF; Porter JP; Wanaka Y; Inagami T
Circ Res; 1998 Mar; 82(5):523-31. PubMed ID: 9529156
[TBL] [Abstract][Full Text] [Related]
5. Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling.
Postina R; Kojro E; Fahrenholz F
Adv Exp Med Biol; 1998; 449():371-85. PubMed ID: 10026828
[TBL] [Abstract][Full Text] [Related]
6. Molecular pharmacology and modeling of vasopressin receptors.
Thibonnier M; Coles P; Thibonnier A; Shoham M
Prog Brain Res; 2002; 139():179-96. PubMed ID: 12436935
[TBL] [Abstract][Full Text] [Related]
7. Amino acids in the COOH-terminal region of the oxytocin receptor third intracellular domain are important for receptor function.
Zhong M; Parish B; Murtazina DA; Ku CY; Sanborn BM
Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E977-84. PubMed ID: 17148753
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning and functional characterization of the oxytocin receptor from a rat pancreatic cell line (RINm5F).
Jeng YJ; Lolait SJ; Strakova Z; Chen C; Copland JA; Mellman D; Hellmich MR; Soloff MS
Neuropeptides; 1996 Dec; 30(6):557-65. PubMed ID: 9004255
[TBL] [Abstract][Full Text] [Related]
9. A serine cluster prevents recycling of the V2 vasopressin receptor.
Innamorati G; Sadeghi HM; Tran NT; Birnbaumer M
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2222-6. PubMed ID: 9482866
[TBL] [Abstract][Full Text] [Related]
10. Lysine 270 in the third intracellular domain of the oxytocin receptor is an important determinant for G alpha(q) coupling specificity.
Yang M; Wang W; Zhong M; Philippi A; Lichtarge O; Sanborn BM
Mol Endocrinol; 2002 Apr; 16(4):814-23. PubMed ID: 11923477
[TBL] [Abstract][Full Text] [Related]
11. Molecular pharmacology of human vasopressin receptors.
Thibonnier M; Conarty DM; Preston JA; Wilkins PL; Berti-Mattera LN; Mattera R
Adv Exp Med Biol; 1998; 449():251-76. PubMed ID: 10026814
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 4,5-bisphosphate (PIP2)-enhanced G protein-coupled receptor kinase (GRK) activity. Location, structure, and regulation of the PIP2 binding site distinguishes the GRK subfamilies.
Pitcher JA; Fredericks ZL; Stone WC; Premont RT; Stoffel RH; Koch WJ; Lefkowitz RJ
J Biol Chem; 1996 Oct; 271(40):24907-13. PubMed ID: 8798768
[TBL] [Abstract][Full Text] [Related]
13. Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells.
Zhu W; Tilley DG; Myers VD; Coleman RC; Feldman AM
Mol Pharmacol; 2013 Aug; 84(2):227-35. PubMed ID: 23690069
[TBL] [Abstract][Full Text] [Related]
14. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
[TBL] [Abstract][Full Text] [Related]
15. Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes.
Hawtin SR; Howard HC; Wheatley M
Biochem J; 2001 Mar; 354(Pt 2):465-72. PubMed ID: 11171127
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.
Andrés M; Trueba M; Guillon G
Br J Pharmacol; 2002 Apr; 135(7):1828-36. PubMed ID: 11934825
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation and desensitization of human endothelin A and B receptors. Evidence for G protein-coupled receptor kinase specificity.
Freedman NJ; Ament AS; Oppermann M; Stoffel RH; Exum ST; Lefkowitz RJ
J Biol Chem; 1997 Jul; 272(28):17734-43. PubMed ID: 9211925
[TBL] [Abstract][Full Text] [Related]
18. Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor.
Wesley VJ; Hawtin SR; Howard HC; Wheatley M
Biochemistry; 2002 Apr; 41(16):5086-92. PubMed ID: 11955056
[TBL] [Abstract][Full Text] [Related]
19. Identification of agonist binding sites of vasopressin and oxytocin receptors.
Mouillac B; Chini B; Balestre MN; Jard S; Barberis C; Manning M; Tribollet E; Trumpp-Kallmeyer S; Hoflack J; Elands J
Adv Exp Med Biol; 1995; 395():301-10. PubMed ID: 8713980
[TBL] [Abstract][Full Text] [Related]
20. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions.
Mouillac B; Chini B; Balestre MN; Elands J; Trumpp-Kallmeyer S; Hoflack J; Hibert M; Jard S; Barberis C
J Biol Chem; 1995 Oct; 270(43):25771-7. PubMed ID: 7592759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
